Your Followed Topics

Top 2 the netherlands News Today

#1
Warning over cosmetic face fillers as scans reveal new details of risks
#1 out of 23.9K est. views
health23h ago

Warning over cosmetic face fillers as scans reveal new details of risks

  • UK experts urge ultrasound guidance before facial filler injections to reduce risk of vascular occlusion.
  • A 100-patient study found ultrasound revealed blocked blood flow in facial vessels in many cases.
  • Experts say ultrasound can guide treatment and improve outcomes for vascular complications.
  • The British Association of Aesthetic Plastic Surgeons notes ultrasound use is rising but not yet standard care.
  • UK government plans to tighten controls, licensing high-risk cosmetic procedures.
  • Clinics are urged to map blood vessels before injections to improve safety.
  • Ultrasound is non-invasive and has no known harmful effects according to experts.
  • The study spans centers in Brazil, Colombia, Chile, the Netherlands, and the United States.
  • Experts call for tighter safeguards as public consultation on new rules begins in 2026.
  • Officials emphasize the importance of ultrasound in preventing complications and guiding treatment.
Vote 0
0
#2
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
#2 out of 2
health12h ago

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

  • Pharvaris N.V. reports topline Rapideminus-3 Phase III data on deucrictibant.
  • The company emphasizes progression in its multi-phase clinical program.
  • No additional statistical details were provided in the referenced communication.
  • The report signals ongoing evaluation for potential regulatory discussions.
  • Rapideminus-3 results are framed as a step forward in the program’s clinical development.
  • The reference notes that exclusive details were not disclosed in the article.
  • Topline data focus on deucrictibant's performance in Rapideminus-3.
  • No location or date specifics were provided in the referenced material.
  • The article serves as a summary of topline data rather than a full trial report.
  • The source publication is Seeking Alpha, referencing Pharvaris N.V.'s topline update.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement